Table 7.
Tumor volumes, T/C and TGI after treatment of WXFL-152 in subcutaneous xenograft models of mice (mean ± SEM).
| Group | Mouse number (n) | Tumor volume at Day 21 (mm3) | T/C (%) | TGI (%) | P value |
|---|---|---|---|---|---|
| A549 Cell line model | |||||
| Control | 9 | 1489 ± 138 | / | / | / |
| WXFL-152 (50 mg/kg) | 9 | 430 ± 42 | 29 | 78 | <0.0001 |
| WXFL-152 (100 mg/kg) | 8 | 401 ± 38 | 27 | 80 | <0.0001 |
| Nintedanib (100 mg/kg) | 9 | 391 ± 43 | 26 | 80 | <0.0001 |
| NCI-H520 Cell line model | |||||
| Control | 6 | 1261 ± 186 | / | / | / |
| WXFL-152 (50 mg/kg) | 6 | 704 ± 107 | 58 | 51 | 0.0415 |
| WXFL-152 (100 mg/kg) | 6 | 478 ± 85 | 36 | 72 | 0.0014 |
| Nintedanib (100 mg/kg) | 6 | 585 ± 101 | 45 | 62 | 0.0057 |
| Liver cancer PDX model | |||||
| Control | 8 | 1026 ± 199 | / | / | / |
| WXFL-152 (200 mg/kg) | 6 | 334 ± 69 | 35 | 76 | 0.0097 |
| Sorafenib (60 mg/kg) | 6 | 304 ± 73 | 31 | 80 | 0.0182 |